Background Sarcopenia, obesity and sarcopenic obesity have been linked to impaired outcome after liver surgery. Preoperative liver function of sarcopenic, obese and sarcopenic-obese patients might be reduced, possibly leading to more post-operative morbidity. The aim of this study was to explore whether liver function and volume were influenced by body composition in patients undergoing liver resection.
Introduction
In the past decade, indications for liver surgery have changed dramatically. This was mainly due to improvements in surgical technique and new insights in the field of oncology and chemotherapy, which led to larger liver resections.
1,2 Despite more extensive preoperative assessment of patients undergoing major liver surgery, post-resectional liver failure still occurs and it remains the most frequent cause of death following major liver surgery. [3] [4] [5] Today, preoperative volumetric and, if needed, functional assessment of the liver are the cornerstones in the pursuit of safe resection liver surgery. [6] [7] [8] [9] As primary or secondary liver tumours often are accompanied by weight loss and cachexia, disturbances in body composition and metabolic state are now suggested to be risk factors for the development of major post-operative morbidity and post-resectional liver failure. 10 Recently, our group showed that depletion of muscle mass (i.e. sarcopenia) negatively influences total liver volume in patients undergoing liver surgery. 11 Several other studies have indicated that disturbances in body composition possibly have negative effects on outcome after liver surgery. 10, [12] [13] [14] [15] [16] The increased complication rates in patients with body composition disturbances (i.e. sarcopenia, obesity and sarcopenic obesity) might well be partially caused by impaired liver function.
Therefore, the aim of the present study was to explore whether total liver function and volume are influenced by sarcopenia, obesity and sarcopenic obesity in patients undergoing extensive preoperative assessment prior to potential liver surgery.
Materials and methods

Patients
This study was conducted according to the revised version of the Declaration of Helsinki (October 2008, Seoul) . From January 2011 to December 2012, all consecutive patients undergoing a LiMAx 6, 7 liver function breath test and a CT scan as part of regular preoperative assessment in the Aachen University Hospital were included. Informed consent was obtained in every patient. The decision for LiMAx evaluation was based on clinical indications (such as resection of four or more liver segments and known or suspected fibrosis or cirrhosis) and was made by the responsible surgeons. Patients underwent extensive preoperative laboratory testing, and Child-Pugh 17 and model for endstage liver disease (MELD) 18 scores were calculated. Jaundice was defined as a serum bilirubin level greater than 2.5 per decilitre. 19 Patients who underwent portal vein embolization (PVE) prior to resection were studied before the PVE procedure.
Methods
Liver function test
The LiMAx test was used to assess hepatocyte-specific metabolic function. This test is based on metabolization of 13 C-labelled methacetin (Euriso-top, Saint-Aubin Cedex, France) by the cytochrome P450 1A2 enzyme in the liver. 6, 7 After intravenous injection, 13 C-labelled methacetin is instantly metabolized, and the ratio between exhaled 13 CO 2 and normal non-enriched background 12 CO 2 is registered over a period of 60 min. 7 Liver volumetry A 2.4 GHz Intel Core 2 Duo MacBook (Apple Inc., Cupertino, CA, USA) with Osirix ® software version 4.1.1 (http://www. osirix-viewer.com) was used for volumetric analysis of the liver. Liver contour was manually outlined by one researcher (T.M.L.) on transverse slices of the venous phase of routinely performed preoperative contrast-enhanced CT scans. Total liver volume (TLV) and tumour volume were measured as described earlier. 20 The non-tumour total liver volume (ntTLV) was calculated by subtracting tumour volume from TLV.
Body composition
Presence of sarcopenia was assessed through measurements of skeletal muscle areas by one single researcher (T.M.L.) with the use of the Osirix ® programme on contrast-enhanced preoperative (or pre-PVE in case of a PVE) CT scans. A threshold range between À30 and 110 Hounsfield units was set to semiautomatically outline muscle areas at the transversal level of the third lumbar vertebra (L3) as recently described. 11 The mean of measurements on two adjacent CT slices at L3 level was used to calculate the L3 skeletal muscle index (L3 MI) by correcting it for height. Sarcopenia was defined as a L3 MI < 41 cm 2 /m 2 in women, <43 cm 2 /m 2 in men with a body mass index (BMI) of <25 and <53 cm 2 /m 2 in men with a BMI of >25 as these cut-off values showed an association with mortality. 21 The ntTLV-bodyweight ratio (%) was calculated using the following formula: [ntTLV (mL)/bodyweight (g)] * 100%. Body surface area was estimated using the Mosteller formula, 22 {[height (cm) * weight (kg)]/3600} 0.5
. Total fat-free body mass (kg) was estimated as 0 · 30 * (skeletal muscle surface area at L3 in cm 2 ) + 6.06. 23 Body-fat% was calculated as [body weight (kg) À fat-free body mass (kg)]/body weight (kg). Obesity was based on body-fat%; cut-off values for obesity were >49.6% for women and >37.5% for men, based on the top two body-fat% quintiles in our study as is conventional for studies evaluating sarcopenic obesity. [24] [25] [26] Sarcopenic obesity was defined as the presence of both sarcopenia and obesity according to our definitions.
Histopathology
One pathologist (N.G.) performed all pathologic examinations. Fibrosis of background liver tissue was classified using the Metavir score, which among others consists of a five-point fibrotic scale. 27 The degree of non-alcoholic steatohepatitis (NASH) was analysed using the NASH scoring system (NAS score). 28 Finally, sinusoidal dilatation was scored as a four-point scale as a measure of sinusoidal obstruction syndrome. 29 Outcome after surgery Post-operative morbidity was graded according to the DindoClavien classification. 30 Complications with a grade ≥ 3a were considered major complications. Thirty-day and 90-day mortality were scored. ). Also, patients without pathologic examination of liver tissue were excluded for correlation analysis. Correlations were calculated with Pearson's test. The resulting regression line was described as a linear equation, and the correlation coefficient (r) was calculated. Relevant clinicopathologic variables associated with liver function were examined using univariable and, where applicable, multivariable linear regression. For the multivariable models, a univariable inclusion criterion of P ≤ 0.15 was used.
Statistical analysis
Results
Patients
A total of 80 patients were included in the present study. The patient characteristics, body composition and liver-related measurements are presented in detail in Tables 1 and 2 . Indications for potential liver resection were mostly cholangiocarcinoma (n = 28, 35.0%), colorectal liver metastases (n = 24, 30.0%) and hepatocellular carcinoma (n = 15, 18.8%).
Influence of sarcopenia on liver volume and function
The median L3 MI was 50.7 (31.9-68.3) cm 2 /m 2 in men and 41.6 (28.7-71.9) cm 2 /m 2 in women. Based on the predefined criteria, 18 (35.3%) men and 13 (44.8%) women were sarcopenic (Table 2) . Table 3 shows the features associated with sarcopenia, obesity and sarcopenic obesity. The median preoperative LiMAx value and non-tumour TLV were 326 (95-684) μg/kg/h and 1571 (869-2852) mL, respectively (Table 2) . No statistically significant difference in liver function was observed between patients with or without sarcopenia [327 (95-684) μg/kg/h and 324 (125-594) μg/kg/h, respectively, P = 0.917]. Sarcopenic patients also had a comparable ntTLV compared with patients without sarcopenia [1518 (869-2581) vs. 1678 (1052-2852) mL, P = 0.215] ( Table 3) .
Influence of obesity on liver volume and function According to our cut-off body-fat% values for obesity, 11 (37.9%) women and 21 (41.2%) men were obese ( Table 2 ). The L3 MI in women was comparable between the two groups. On the contrary, in obese men, the L3 MI was significantly smaller compared to that of non-obese men [42.9 (31.9-68. Table 3) .
Influence of sarcopenic obesity on liver volume and function Eighteen (22.5%) patients met the criteria for sarcopenic obesity, and sarcopenic-obese patients were predominantly male (83.3%) ( Table 2) . Sarcopenic-obese patients were older than patients without sarcopenic obesity [72 (43-82) vs. 65 (28-80), P = 0.029]. NtTLV and LiMAx values were comparable between patients with and without sarcopenic obesity (Table 3) . (Figures 1 and 2) . Therefore, 51 (63.8%) patients without severe background liver disease were analysed. We found no correlation between the LiMAx test and ntTLV (r = 0.06, P = 0.679) (Figure 1 ). Weight (r = À0.40, P = 0.003), body surface area (r = À0.32, P = 0.023), estimated body-fat% (r = À0.43, P < 0.002) and BMI (r = À0.47, P < 0.001) showed a weak but significant negative correlation with the LiMAx test outcome. No correlation was found between the LiMAx test and L3 MI (r = 0.09, P = 0.550) or fat-free body mass (r = 0.09, P = 0.538) (Figure 2) . A significant but weak correlation between the L3 MI and ntTLV was found (r = 0.41, P = 0.003). Moreover, fat-free body mass (r = 0.60, P < 0.001), body surface area (r = 0.66, P < 0.001), weight (r = 0.58, P < 0.001), height (P = 0.60, r < 0.001) and BMI (r = 0.29, P = 0.042) were all weak but significantly correlated with ntTLV ( Figure 2 ).
Histology
Cirrhosis was present in 8.3% of all patients, and all were men. None of the patients had NASH (Table 2) . However, 21.1% of the patients had borderline NASH (NAS = 3-4). Of the non-obese and obese, 13.9% and 38.1% were considered as having borderline NASH (P = 0.036). Obese patients also showed a significantly higher preoperative C-reactive protein level [19 (1-187) vs. 8 (1-95) mg/L, P = 0.007] ( Table 3) . Severe sinusoidal dilatation as an indication for sinusoidal obstruction syndrome was present in 5.3% of the patients.
Predictors of decreased liver function LiMAx value
After univariable analysis, seven variables were considered significant negative prognostic factors for LiMAx liver function values, namely BMI (P = 0.001), obesity (P = 0.013), fat mass (P < 0.001), body-fat% (P < 0.001), body surface area (P = 0.022), INR (International Normalized Ratio) (P = 0.012) Sarcopenia, obesity and sarcopenic obesity and sinusoidal dilatation (P = 0.019). One additional borderline significant (P ≤ 0.15) variable was selected for multivariable analysis, namely female sex (P = 0.118) ( Table 4) . Because of possible collinearity with body-fat%, five (borderline) significant negative prognostic factors were excluded for multivariable analysis, that is, BMI, obesity, fat mass, body surface area and NAS score. Using multivariable analysis, only body-fat% was identified as an independent negative prognostic factor influencing the liver function with a regression coefficient (standard error) of À3.2 (1.2), P = 0.011. Presence of chemotherapy-induced sinusoidal dilatation also showed a tendency to decrease liver function with a regression coefficient of À34.4 (17.7), P = 0.057.
Outcome after liver resection
Complications and survival were evaluated in 57 (71.2%) patients who had undergone liver resection. Complications and major complications occurred in 19 (33.3%) and 17 (29.8%) patients, respectively. Most frequent complications were intraabdominal abscess (n = 8, 14.0%), bile leakage (n = 7, 12.3%), biloma (n =4, 7.0%), sepsis (n = 4, 7.0%) and intra-abdominal haemorrhage (n = 3, 5.3%). One patient developed postresectional liver failure (1.8%), and another patient developed hepatic encephalopathy (1.8%). There were no differences in major complication rates between sarcopenic and non-sarcopenic patients (P = 0.392), obese and non-obese (P = 0.530) and patients with and without sarcopenic obesity (P = 0.765). Thirty-day and 90-day mortality rates were 3.5% (n = 2) and 10.5% (n = 6). There were also no significant differences in 90-day mortality rates between patients with and without sarcopenia (P = 0.624), obesity (P = 0.486) or sarcopenic obesity (P = 0.487).
Discussion
This study aimed to assess how liver function and volume relate to sarcopenia, obesity and sarcopenic obesity in patients undergoing extensive preoperative assessment prior to potential liver surgery. We showed that sarcopenic and sarcopenic-obese patients did not have diminished liver function compared with patients without sarcopenia or sarcopenic obesity, evidenced by comparable LiMAx values prior to surgery. Obese patients however showed significantly reduced LiMAx values compared with patients without obesity, and body-fat% was identified as an independent negative factor affecting liver function. Moreover, there were significant negative correlations between the LiMAx values and body-fat%, body surface area, weight and BMI, which confirmed that obesity influenced liver function. Differences in ntTLV between sarcopenic and non-sarcopenic, obese and non-obese and sarcopenic-obese and patients without sarcopenic obesity did not reach statistical significance. Recently, we demonstrated that liver volume was associated with the L3 MI, whereby sarcopenic patients had smaller ntTLVs compared with patients without sarcopenia. 11 In the present study, we found comparable ntTLVs in patients with and without sarcopenia.
Nevertheless, the L3 MI was correlated with ntTLV, indicating that muscle wasting is somehow associated with smaller livers. As only patients at risk of developing postoperative liver failure (i.e. large resections) underwent a LiMAx test, a selection bias may have influenced our findings. Whereas the majority of patients in our previous study suffered from colorectal cancer liver metastases, more patients with intrahepatic cholangiocarcinoma or Klatskin tumours were included in the present study. The difference in metabolic behaviour could explain the absence of a significant difference between the ntTLVs of sarcopenic and non-sarcopenic patients and lower correlation coefficient between L3 MI and liver volume in the present study (r = 0.41 vs. r = 0.64 in the previous study). This study also assessed (LiMAx) liver function values in relation with sarcopenia. The present data do not support the idea that the increased post-operative morbidity, earlier recurrence and shorter survival in sarcopenic patients 10, 12, 16 could be explained by a decline in preoperative liver function. However, sarcopenia or muscle wasting remains an important factor negatively influencing outcome through hypercatabolism, hypoanabolism and, as a result, reduced reserves.
Only few studies have been performed on the effect of obesity on morbidity, overall survival and disease-free survival in the surgical treatment of primary or secondary liver tumours. Recently, Cauchy et al. showed that the metabolic syndrome even in absence of overt steatosis adversely affected outcome.
14 Also, in other fields of oncologic surgery, obesity has been identified as an important factor affecting outcome. [31] [32] [33] [34] In the present study, body-fat%, body surface area, BMI and weight all showed a significant negative correlation with liver function LiMAx values. Moreover, body-fat% was identified as an independent factor negatively affecting the liver function. The significantly decreased LiMAx values in obese patients were accompanied by an increase in borderline NASH as could be expected. 35, 36 We showed a trend that obese patients had larger livers and a positive correlation between liver volume and bodyweight, BMI and body surface area. Thus, obese patients have larger, although less functioning, livers probably due to deposition of fat, presumably increasing the risk of developing morbidity. We found no disadvantageous consequences of sarcopenic obesity on liver volume or function. This is probably due to the small number of sarcopenic-obese patients and the heterogeneity of the indications for liver resection. However, it may be that sarcopenic-obese patients have an increased risk of post-operative morbidity as sarcopenia and obesity independently of one another proved to be risk factors for post-operative complications. 10, 14, 16 Differences in complication and mortality could however not be confirmed in this study, but this may relate to the sample size.
Body composition features have been calculated based on preoperative CT scans, body weight and length, and CT scanning is considered the gold standard for estimating muscle mass or lean body mass. 37 The use of body-fat% instead of BMI might be a better method of defining obesity as it prevents that muscular patients (with a BMI of >30) are incorrectly indicated as obese. Moreover, body-fat% is able to identify obesity in thin patients. The sample size and heterogeneity of our population are relative drawbacks of our study. Therefore, further investigations of the influence of body composition on short-term and long-term outcome after liver surgery are of major importance.
In conclusion, sarcopenia and sarcopenic obesity did not seem to influence liver volume or function negatively. However, obese patients have larger but less functional livers compared with those of non-obese patients. This indicates dissociation of function and volume most likely due to deposition of fat. Moreover, body-fat% seemed to be an independent factor affecting liver function negatively. The influence of obesity on morbidity after liver resection should therefore be taken into account as a part of routine preoperative assessment to prevent post-resectional liver failure especially in centres were no standard liver function evaluation is performed before major liver surgery. Excluded from multivariable analysis due to possible collinearity.
